About OxSyBio
OxSyBio is a company based in London (United Kingdom) founded in 2014 by John Hagan Pryce Bayley. OxSyBio has raised $16.35 million across 3 funding rounds from investors including IP Group, Woodford Investment Management and Parkwalk. The company has 285 employees as of March 31, 2024. OxSyBio operates in a competitive market with competitors including Nuclera Nucleics, Aspect Biosystems, CELLINK, Collplant and Triastek, among others.
- Headquarter London, United Kingdom
- Employees 285 as on 31 Mar, 2024
- Founders John Hagan Pryce Bayley
- Stage Minicorn
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name James And James Fulfilment Ltd
- Date of Incorporation 12 Feb, 2010
- Jurisdiction NORTHAMPTON, ENGLAND
-
Annual Revenue
$44.8 M (USD)31as on Dec 31, 2022
-
Net Profit
-$983.33 K (USD)-129as on Dec 31, 2022
-
EBITDA
-$1.51 M (USD)-143as on Dec 31, 2022
-
Total Equity Funding
$16.35 M (USD)
in 3 rounds
-
Latest Funding Round
$13.87 M (USD), Series A
Feb 14, 2018
-
Investors
IP Group
& 2 more
-
Employee Count
285
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of OxSyBio
OxSyBio has successfully raised a total of $16.35M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $13.87 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OxSyBio
OxSyBio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include IP Group, Woodford Investment Management and Parkwalk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Locked | Locked | Locked | |
|
Venture capital and advisory services are offered across multiple sectors.
|
Locked | Locked | Locked | |
|
Diversified investment portfolios are managed for clients by the firm.
|
Locked | Locked | Locked |
Investor details for OxSyBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OxSyBio
Investment portfolio details for OxSyBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OxSyBio
Detailed financials for OxSyBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxsybio Comparisons
Peer comparison for OxSyBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OxSyBio
OxSyBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, Aspect Biosystems, CELLINK, Collplant and Triastek, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
Bioprinting technology and tissue therapeutics for regenerative medicine are developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
Provider of 3D printing pharmaceutical technology platform for drug design
|
|
| Locked | Locked | Locked |
4D bio-printer solutions for tissue regeneration are provided.
|
Detailed competitors of OxSyBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxsybio
Complete news archive for OxSyBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OxSyBio
OxSyBio was founded in 2014.
OxSyBio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
OxSyBio is a funded company, having raised a total of $16.35M across 3 funding rounds to date.
As of Mar 31, 2024, the latest employee count at OxSyBio is 285.
Annual revenue of OxSyBio is $44.8M as on Dec 31, 2022.
Provider of 3D printing of tissue biomaterials for medical research and clinical applications. Its 3D printer claims to produce a range of tissue-like and functional tissues which claim to aid in testing drugs and, eventually structures for use in surgical repair. It is also planning to include living cells in the tissue-like materials and to refine the printer so it can produce even more complex structures, enabling the creation of living tissue samples.
OxSyBio's top competitors include Nuclera Nucleics, Aspect Biosystems and Allevi.
OxSyBio has 3 investors. Key investors include IP Group, Woodford Investment Management, and Parkwalk.
The valuation of OxSyBio is $22.65M as of Feb 2018.